Skip Navigation


Rheumatology Advance Access originally published online on March 27, 2008
Rheumatology 2008 47(5):738-739; doi:10.1093/rheumatology/ken113
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/5/738    most recent
ken113v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Burr, M. L.
Right arrow Articles by Östör, A. J. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burr, M. L.
Right arrow Articles by Östör, A. J. K.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis

M. L. Burr1, A. P. Malaviya1, J. H. Gaston1, A. J. Carmichael2 and A. J. K. Östör1

1Department of Rheumatology and 2Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge, UK.

Correspondence to: M. L. Burr, Rheumatology Research Unit, Addenbrooke's Hospital, Box 194 E6, Hills Road, Cambridge CB2 2QQ, UK. E-mail: marianlburr@doctors.org.uk

The first 10% of the full text of this article appears below.

SIR, The link between anti-TNF therapy and reactivation of latent tuberculosis (TB) is well recognized [1–3]. These patients are more likely to present with disseminated infection and this carries considerable mortality. Managing active RA in patients with anti-TNF-associated TB can therefore be challenging. We present the case of a patient with RA who was successfully treated with rituximab, a chimaeric anti-CD20 monoclonal antibody, after developing disseminated isoniazid-resistant TB following treatment with infliximab.

A 54-yr-old white female with a 15-yr history of severe . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?